Investigating how KIR2DL2 affects T-cell function in cancer treatment
KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function
This study is looking at how a specific receptor on T-cells, called KIR2DL2, affects their ability to fight pancreatic cancer, with the goal of finding better ways to improve immunotherapy treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10813170 on NIH RePORTER |
What this research studies
This research explores the role of KIR2DL2, a receptor found on certain T-cells, in regulating their ability to fight cancer. It examines how KIR2DL2 expression influences T-cell activation and survival, particularly in the context of adoptive cell therapies for pancreatic cancer. By studying the effects of KIR2DL2 on T-cell behavior, the research aims to identify ways to enhance the effectiveness of immunotherapy treatments for patients. The approach includes both laboratory experiments and analysis of patient samples to understand the implications of KIR2DL2 in cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with pancreatic cancer who are undergoing or considering adoptive cell therapy.
Not a fit: Patients with cancers other than pancreatic cancer or those not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies that enhance T-cell responses against tumors, potentially increasing survival rates for cancer patients.
How similar studies have performed: Previous research has shown that targeting immune checkpoints can enhance T-cell responses in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Abate-Daga, Daniel — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Abate-Daga, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.